Published in Structure on October 22, 2015
Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget (2016) 0.92
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat Commun (2016) 0.86
Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab. Cell Res (2016) 0.84
Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy. Cell Res (2016) 0.83
Rapid PD-L1 detection in tumors with PET using a highly specific peptide. Biochem Biophys Res Commun (2016) 0.81
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nat Commun (2017) 0.80
T cell Bim levels reflect responses to anti-PD-1 cancer therapy. JCI Insight (2016) 0.79
Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Protein Cell (2016) 0.78
How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures. ChemMedChem (2015) 0.78
The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3. Immunol Rev (2017) 0.77
High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1. Sci Rep (2016) 0.76
Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor. Oncotarget (2016) 0.75
High-dose irradiation in combination with toll-like receptor 9 agonist CpG oligodeoxynucleotide 7909 downregulates PD-L1 expression via the NF-κB signaling pathway in non-small cell lung cancer cells. Onco Targets Ther (2016) 0.75
Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant. Structure (2016) 0.75
Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015). Expert Opin Ther Pat (2016) 0.75
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discov (2017) 0.75
In situ and in silico kinetic analyses of programmed cell death-1 (PD-1) receptor, programmed cell death ligands, and B7-1 protein interaction network. J Biol Chem (2017) 0.75
Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy. EBioMedicine (2017) 0.75
PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. J Hematol Oncol (2017) 0.75
A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol (2017) 0.75
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8(+) T Cell Responses to Chronic Viral Infections and Cancer. Front Immunol (2017) 0.75
When theory meets experiment: the PD-1 challenge. J Mol Model (2017) 0.75
Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma. Mol Cell Proteomics (2017) 0.75
PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr (2010) 108.52
Phaser crystallographic software. J Appl Crystallogr (2007) 108.34
Features and development of Coot. Acta Crystallogr D Biol Crystallogr (2010) 89.46
XDS. Acta Crystallogr D Biol Crystallogr (2010) 67.46
Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr (2005) 61.38
REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr (2011) 39.32
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
T cell exhaustion. Nat Immunol (2011) 11.08
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010) 6.24
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 6.17
Oncology meets immunology: the cancer-immunity cycle. Immunity (2013) 5.60
Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10
A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov (2007) 4.82
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A (2010) 3.12
Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature (2001) 2.42
Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature (2001) 2.21
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc Natl Acad Sci U S A (2008) 2.03
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer (2007) 2.00
Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res (2011) 1.97
The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat (2013) 1.84
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther (2015) 1.73
Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity (2004) 1.70
Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists. PLoS One (2012) 1.60
Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proc Natl Acad Sci U S A (2008) 1.55
Experiences in fragment-based drug discovery. Trends Pharmacol Sci (2012) 1.41
Role of the PD-1 pathway in the immune response. Am J Transplant (2012) 1.35
Structure and interactions of the human programmed cell death 1 receptor. J Biol Chem (2013) 1.27
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer (2015) 1.25
Biomarkers in cancer immunotherapy. Cancer Cell (2015) 1.16
A dimeric structure of PD-L1: functional units or evolutionary relics? Protein Cell (2010) 1.11
PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol Immunother (2014) 1.08
Structures of PD-1 with its ligands: sideways and dancing cheek to cheek. Proc Natl Acad Sci U S A (2008) 1.00
Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy. Angew Chem Int Ed Engl (2014) 0.91
Hot spot-based design of small-molecule inhibitors for protein-protein interactions. Bioorg Med Chem Lett (2014) 0.90
Programmed cell death-1 inhibition in lymphoma. Lancet Oncol (2015) 0.81
Checkpoint inhibitors for cancer immunotherapy. Multiple checkpoints on the long road towards cancer immunotherapy. Immunol Cell Biol (2015) 0.77